PIK3CA and colorectal carcinoma: Until now, the utility of CLDN1 and CLDN7 dysregulation and their association with PIK3CA, SLC6A6, ASAP-1, and TMEM-43 has not been studied, nor has it been used to predict the risk of recurrence or chemoresistance in CRC patients.